Cannabinoids have demonstrated anti-carcinogenic properties in a variety of malignancies, including in prostate cancer”, states researchers. In the present study, they “explored the anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer.”
For the study, “Established prostate cancer cells (PC3, DU145, LNCaP) were treated with varying concentrations of WIN”, and “Cell proliferation was determined by the MTS assay.” The anti-migration and anti-invasive potential of WIN “was examined by the wound healing assay and the matrigel invasion assay.” Cell cycle analysis was performed by flow cytometry, and mechanistic studies were performed by Western blot.
Animals were randomised into two groups: saline control and WIN (5 mg/kg), delivered by intraperitoneal injection three times per week for 3 weeks.
“WIN significantly reduced prostate cancer cell proliferation, migration, invasion, induced apoptosis, and arrested cells in Go/G1 phase in a dose-dependent manner”, claim researchers.
They conclude; “The following study provides evidence supporting the use of WIN as a novel therapeutic for prostate cancer.”